Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352560 | 0.90 | MAPT (0.51) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL3355952 | 0.87 | TLR7 (0.48) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL5617942 | 0.87 | ENPP2 (0.44) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL5618891 | 0.86 | GAA (0.43) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL6759213 | 0.85 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL27666505 | 0.84 | TLR7 (0.44) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL5618924 | 0.84 | ENPP2 (0.43) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL5618823 | 0.83 | TNF (0.47) | TP53LMNAGAAHTTENPP2 | |
| SCHEMBL1952080 | 0.83 | GAA (0.52) | TP53LMNAGAAHTTMAPT | |
| SCHEMBL3353897 | 0.82 | TLR7 (0.47) | TP53LMNAGAAHTTENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894165-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040204436-A1 | Imidazonaphthyridines | MEDICIS PHARMACEUTICAL CORPORATION | 2004-10-14 | — | — | US | disclosed |
| CN-1154647-C | Imidazo 1, 5-naphthyridines and their use in eliciting cytokine biosynthesis | 3M | 2004-06-23 | — | — | CN | disclosed |
| US-6699878-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-03-02 | — | — | US | disclosed |
| CN-1284957-A | Imidazonaphthyridines and their use in inducing cytokine biosynthesis | MINNESOTA MINING & MFG (US) | 2001-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204436-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TP53 68/4885LMNA 3209/4885GAA 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.